Defining cellular receptors for the Bacillus cereus hemolysin BL toxin (HBL) and the development of anti-HBL therapies
蜡样芽孢杆菌溶血素 BL 毒素 (HBL) 细胞受体的定义和抗 HBL 疗法的开发
基本信息
- 批准号:10327318
- 负责人:
- 金额:$ 50.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-21 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAnimalsAnthrax diseaseBacillus cereusBacteriaBindingBlindnessCRISPR screenCRISPR/Cas technologyCell Surface ReceptorsCellsCessation of lifeChildClinical ManagementClustered Regularly Interspaced Short Palindromic RepeatsComplementCultured CellsCytolysisDataDevelopmentEndophthalmitisGenesGram-Positive BacteriaHealthHemolysinHistologyHumanImmunocompetentImmunocompromised HostIn VitroInfectionIntegration Host FactorsInvestigationInvestigational TherapiesKnock-outKnockout MiceKnowledgeLibrariesLinkLipopolysaccharidesMediatingMolecularMusMutagenesisNosocomial InfectionsPathogenesisPneumoniaProteinsReceptor GeneReportingReproduction sporesResistanceRoleTNF geneTargeted ToxinsTestingTherapeuticTissuesToxinTransgenic MiceVirulenceVirulence FactorsWorkalpha Toxinbasecell typecytotoxicitydeep sequencingeffective therapyexpectationfoodborne outbreakgenome-widehuman pathogenin vivomacrophagemouse modelnanomolarnovel therapeuticspathogenpathogenic bacteriarapid diagnosisreceptorrestorationscreeningtargeted treatmenttherapeutically effectivewhole genome
项目摘要
Abstract
Bacillus cereus, a spore-forming, gram-positive bacterium, is a human pathogen commonly associated with
hospital infections and foodborne outbreaks. Increasingly, B. cereus has been identified as a cause of acute
severe infections and deaths in immunocompromised patients and children. One of B. cereus’ virulence factors
is the highly potent pore-forming toxin, hemolysin BL (HBL). However, the mechanisms underlying the
interactions between HBL and target cells and the identity of the HBL cellular receptor(s) remains unknown. This
knowledge gap presents significant challenges for developing effective therapies in clinical management of
potentially devastating B. cereus infections. Therefore, in order to develop effective therapeutics, there is a
critical need to identify the toxin cellular receptor(s) and the molecular mechanisms underlying the toxin’s action.
Our earlier preliminary data demonstrated that a cellular receptor is required for the cytolytic action of HBL.
Based on this observation, we performed an unbiased genome-wide CRISPR screen and have identified
Lipopolysaccharide-Induced Tumor Necrosis Factor-α Factor (LITAF) as the major, heretofore elusive, HBL
receptor. Building on this strong preliminary data, in Aim 1, we will determine the in vivo role of LITAF in HBL
pathogenesis in mouse models. To do so, we will characterize the LITAF knockout mice we have generated in
this application, where our preliminary data supports the critical role of LITAF in HBL pathogenesis. We will also
generate LITAF transgenic mice allowing the restoration of LITAF expression in a cell type-specific manner in a
LITAF KO background. These cell type-specific LITAF-expressing mice will allow us to determine the key tissue
targets responsible for HBL-induced lethality. In Aim 2, we will establish whether LITAF is a species-independent
HBL receptor, perform comprehensive mutagenesis studies to identify the key residues of LITAF responsible for
HBL binding, and demonstrate the utility of decoy receptors as anti-HBL therapy.
Our initial CRISPR screen for HBL receptor demonstrated that CRISPR knockout of LITAF in mouse RAW264.7
macrophages resulted in complete resistance to HBL, whereas the same knockout in human HT1080 cells only
yielded a 4-fold increase in resistance. This suggests additional receptor(s) may be involved in HBL-mediated
cytotoxicity within certain cell types. Therefore, in Aim 3, we will delineate the full complement of host factors
required for HBL action via sequential CRISPR screens. Supported by strong preliminary data, we hypothesize
that this alternative receptor or additional host factors would become increasingly important when LITAF is
absent, and can therefore be identified by a CRISPR screen when LITAF knockout cells are used.
Together, this work will open new unbiased strategies for studying interactions between pore-forming toxins and
mammalian target cells, potentially elucidating common mechanisms used by other enteropathogenic bacteria.
These proposed studies will also validate the use of the unbiased stepwise CRISPR
factors hijacked by other toxins in modulating bacterial pathogenesis.
screens to identify host
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shihui Liu其他文献
Shihui Liu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shihui Liu', 18)}}的其他基金
Mechanisms of anthrax lethal toxin-induced mortality and the novel biological-based targeted therapies
炭疽致死毒素致死机制及新型生物靶向治疗
- 批准号:
10654406 - 财政年份:2023
- 资助金额:
$ 50.63万 - 项目类别:
Developmental therapy for selectively targeting MEK-ERK pathway in cancer cells and tumor stromal compartment
选择性靶向癌细胞和肿瘤基质室中 MEK-ERK 通路的发育疗法
- 批准号:
10092258 - 财政年份:2021
- 资助金额:
$ 50.63万 - 项目类别:
Developmental therapy for selectively targeting MEK-ERK pathway in cancer cells and tumor stromal compartment
选择性靶向癌细胞和肿瘤基质室中 MEK-ERK 通路的发育疗法
- 批准号:
10589930 - 财政年份:2021
- 资助金额:
$ 50.63万 - 项目类别:
Developmental therapy for selectively targeting MEK-ERK pathway in cancer cells and tumor stromal compartment
选择性靶向癌细胞和肿瘤基质室中 MEK-ERK 通路的发育疗法
- 批准号:
10386764 - 财政年份:2021
- 资助金额:
$ 50.63万 - 项目类别:
Defining cellular receptors for the Bacillus cereus hemolysin BL toxin (HBL) and the development of anti-HBL therapies
蜡样芽孢杆菌溶血素 BL 毒素 (HBL) 细胞受体的定义和抗 HBL 疗法的开发
- 批准号:
10550183 - 财政年份:2020
- 资助金额:
$ 50.63万 - 项目类别:
Molecular mechanisms and novel biological-based therapies for anthrax lethal toxin-induced mortality
炭疽致命毒素引起的死亡的分子机制和新型生物疗法
- 批准号:
10246693 - 财政年份:2020
- 资助金额:
$ 50.63万 - 项目类别:
Defining cellular receptors for the Bacillus cereus hemolysin BL toxin (HBL) and the development of anti-HBL therapies
蜡样芽孢杆菌溶血素 BL 毒素 (HBL) 细胞受体的定义和抗 HBL 疗法的开发
- 批准号:
9973309 - 财政年份:2020
- 资助金额:
$ 50.63万 - 项目类别:
Defining cellular receptors for the Bacillus cereus hemolysin BL toxin (HBL) and the development of anti-HBL therapies
蜡样芽孢杆菌溶血素 BL 毒素 (HBL) 细胞受体的定义和抗 HBL 疗法的开发
- 批准号:
10112820 - 财政年份:2020
- 资助金额:
$ 50.63万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 50.63万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 50.63万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 50.63万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 50.63万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 50.63万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 50.63万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 50.63万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 50.63万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 50.63万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 50.63万 - 项目类别:
Research Grant














{{item.name}}会员




